Companie

Serum Institute seeks DCGI approval to make Sputnik V

Our Burea Mumbai | Updated on June 03, 2021

Neither the company nor RDIF have made formal announcement on this

Serum Institute of India looks set to add the Russian vaccine Sputnik V to its basket of Covid-19 antidotes. The Pune-based vaccine-maker is said to have approached the Drug Controller General of India (DCGI) to produce this two-dose vaccine.

While Serum chief Adar Poonawalla has in the past indicated that the company has been in talks with the Russian Direct Investment Fund (RDIF) on Sputnik V, neither entity has made a formal announcement on the same. A source confirmed to BusinessLine that the vaccine-maker had approached the regulator to make the vaccine in Pune.

The actual manufacturing is still 4-5 months away, the person indicated, though it was not clear if this was a “fill finish” arrangement.

Serum Covid vaccine alliances include a production tie-up for the AstraZeneca-OxfordUniversity jab. The company expects to up production to 100 million doses a month (from about 70 million), by July. It is also undertaking bridging trials on the Covid vaccine of American company Novavax and expects it to be completed by about September.

Published on June 03, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

vaccines and immunisation
Covid-19
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.